• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    11/14/24 4:08:39 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRIX alert in real time by email
    SC 13G/A 1 ea0220738-sc13ga1sands_nurix.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Nurix Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per shares

    (Title of Class of Securities)

     

    67080M103

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐Rule 13d-1(b)
      ☐Rule 13d-1(c)
      ☒Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

     

     

     

    CUSIP No. 67080M1039

    13G

     

    Page 2 of 5 Pages

     

    1

    NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Arthur T. Sands

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

    3,272,832(1)

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    3,272,832(1)

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,272,832(1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.7%(2)

     

    12

    TYPE OF REPORTING PERSON

    IN

     

     

    (1)Includes (i) 308,333 shares of common stock, (ii) 2,364,499 shares underlying options to purchase common stock that are exercisable within 60 days of September 30, 2024, and (iii) 150,000 shares of common stock held by each of CMS Family Trust DTD, EES Family Trust DTD, IGS Family Trust DTD and LAS Family Trust DTD. Dr. Sands is the trustee of the CMS Family Trust, EES Family Trust, IGS Family Trust and LAS Family Trust.
      
    (2)Based on 67,098,027 shares of the Issuer’s Common Stock outstanding as of September 30, 2024.

     

     

     

     

    CUSIP No. 67080M103

    13G

     

    Page 3 of 5 Pages

      

    Item 1(a) Name of Issuer:
       
      Nurix Therapeutics, Inc.
       
    Item 1(b) Address of Issuer’s Principal Executive Offices:
       
      1700 Owens Street, Suite 205
      San Francisco, CA 94158
       
    Item 2(a) Name of Person Filing:
       
      Arthur T. Sands
       
    Item 2(b) Address of Principal Business Office or, If None, Residence
       
      c/o Nurix Therapeutics, Inc.
      1700 Owens Street, Suite 205
      San Francisco, CA 94158
       
    Item 2(c) Citizenship:
       
      United States
       
    Item 2(d) Title of Class of Securities:
       
      Common Stock, $0.001 par value per share
       
    Item 2(e) CUSIP Number:
       
      67080M103
       
    Item 3. Not applicable.

     

    Item 4. Ownership
         
      (a) Amount Beneficially Owned:  
         
        3,272,832(1)
         
      (b) Percent of Class:
         
        4.7%(2)
         
      (c)   Number of shares as to which the person has:
         
      (i) Sole power to vote or direct the vote:  
           
          3,272,832(1)
           
      (ii) Shared power to vote or direct the vote:
           
          0
           
      (iii) Sole power to dispose or to direct the disposition of:
           
          3,272,832(1)
           
      (iv) Shared power to dispose or to direct the disposition of:
           
          0

     

    (1) Includes (i) 308,333 shares of common stock, (ii) 2,364,499 shares underlying options to purchase common stock that are exercisable within 60 days of September 30, 2024, and (iii) 150,000 shares of common stock held by each of CMS Family Trust DTD, EES Family Trust DTD, IGS Family Trust DTD and LAS Family Trust DTD. Dr. Sands is the trustee of the CMS Family Trust, EES Family Trust, IGS Family Trust and LAS Family Trust.
       
    (2) Based on 67,098,027 shares of the Issuer’s Common Stock outstanding as of September 30, 2024.

     

     

     

    CUSIP No. 67080M1039

    13G

     

    Page 4 of 5 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5% of the class of securities, check the following:  ☒

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person
       
      Not applicable.
       
    Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable.
       
    Item 10. Certifications
       
      Not applicable.

     

     

     

     

    CUSIP No. 67080M1039

    13G

     

    Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024  
     
      By: /s/ Arthur T. Sands
      Name: Arthur T. Sands

     

     

    Get the next $NRIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRIX

    DatePrice TargetRatingAnalyst
    6/29/2026$28.00Outperform
    Oppenheimer
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    11/24/2025$30.00Buy
    Truist
    10/21/2025$24.00Outperform
    Mizuho
    3/17/2025$16.00Market Perform
    Leerink Partners
    12/10/2024$35.00Buy
    BTIG Research
    12/6/2024$35.00Outperform
    BMO Capital Markets
    10/24/2024$35.00Buy
    UBS
    More analyst ratings

    $NRIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes comprehensive clinical development plan in malignant hematology and enables expansion of bexobrutideg into chronic spontaneous urticaria (CSU) and multiple sclerosis (MS) Presented clinical data update at the European Hematology Association (EHA) supporting bexobrutideg's potential as a best-in-class BTK degrader across multiple lines of therapy in CLL Well capitalized with cash, cash equivalents and marketable securities of $443.5 million as of May 31, 2026, and pro-forma cash

    7/9/26 4:01:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

    Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development candidates into pre-IND development in 2027.SAN FRANCISCO, July 6, 2026 /CNW/ -- American News Group News Commentary, Artificial intelligence has become a fixture in biotech marketing, but the more consequential question is where it is actually used: in the slide deck, or at the bench. GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company, says it is applying AI to the latter, embedding AI-bas

    7/6/26 11:19:00 AM ET
    $CTMX
    $GTBP
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

    High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement Data to be presented at the 2026 European Hematology Association (EHA) Congress BRISBANE, Calif., June

    6/11/26 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    SEC Filings

    View All

    SEC Form 10-Q filed by Nurix Therapeutics Inc.

    10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)

    7/9/26 4:12:07 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

    7/9/26 4:09:51 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

    6/11/26 7:06:57 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Ring Christine exercised 11,008 shares at a strike of $5.47 and sold $259,366 worth of shares (11,008 units at $23.56) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    7/2/26 6:02:59 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Hansen Gwenn sold $107,880 worth of shares (5,394 units at $20.00) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 115,005 units (SEC Form 4)

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    6/25/26 6:49:10 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Ring Christine exercised 28,935 shares at a strike of $8.05 and sold $580,506 worth of shares (28,935 units at $20.06) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    6/25/26 6:38:05 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Nurix Therapeutics with a new price target

    Oppenheimer resumed coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $28.00

    6/29/26 8:39:55 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00

    1/8/26 8:12:12 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Nurix Therapeutics with a new price target

    Truist resumed coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $30.00

    11/24/25 9:17:24 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Leadership Updates

    Live Leadership Updates

    View All

    Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

    Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors Basel, 08 June 2026 - Roche ((SIX: RO, ROP, OTCQX:RHHBY) announced today that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX). Under the terms of

    6/8/26 1:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

    NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi

    4/8/25 4:00:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:21:48 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:08:39 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Financials

    Live finance-specific insights

    View All

    Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

    Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) Nurix to receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milesto

    6/8/26 1:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

    600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced t

    10/22/25 6:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

    Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces Nurix's scientific leadership and platform strength in targeted protein degradation Nurix remains on track to initiate pivotal trials of bexobrutideg in 2025 Data are being presented at the 30th European Hematology Association Congress (EHA2025) Company will host a webcast conference call today, June 12, 2025, at 8:00 a.m. ET (2:00 p.m. CEST) SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clin

    6/12/25 6:59:59 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care